Wells Fargo Maintains Equal-Weight on Conmed, Lowers Price Target to $98
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Durgesh Chopra has maintained an Equal-Weight rating on Conmed (CNMD) and reduced the price target from $107 to $98.

February 01, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Wells Fargo analyst Durgesh Chopra maintains an Equal-Weight rating on Conmed and lowers the price target from $107 to $98.
The reduction in price target by a well-regarded analyst could lead to a negative short-term sentiment among investors, potentially causing a decrease in CNMD's stock price. The maintenance of an Equal-Weight rating suggests that the analyst sees the company as fairly valued at its current price, but the lowered target indicates a reassessment of its future growth prospects or market conditions.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100